Could targeting T cells lead to a safer dengue vaccine?

Dengue fever is a tricky target for vaccines. Some existing shots can, in rare cases, make a second infection worse through a process called antibody-dependent enhancement (ADE). That's why researchers are looking for new strategies. A fresh review of the science suggests that vaccines designed to activate T cells—the immune system's special forces—might help control the dengue virus and could play a role in managing ADE risk. The thinking is that a strong T cell response could back up the body's antibody defenses. In early lab tests, a new type of vaccine using mRNA technology (similar to some COVID-19 vaccines) has also shown promise because it's stable and controllable. But here's the crucial catch: the relationship between T cells and ADE is incredibly complex. Scientists warn that getting the balance wrong could potentially cause other immune problems. All of this work is still in the review and early preclinical stage—meaning it's based on analyzing existing studies and tests in animals, not new human trials. There is no data yet on safety or how well it might work in people. The search for a truly safe and effective dengue vaccine continues, and this is one new path being carefully explored.